Sustained Efficacy of Continuous Subcutaneous Insulin Infusion in Type 1 Diabetes Subjects with Recurrent Non-Severe and Severe Hypoglycemia and Hypoglycemia Unawareness: A Pilot Study
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This study evaluated the effect of CSII on hypoglycemia awareness and on glucose profile in type 1 diabetes (T1D) subjects with repeated non-severe or severe hypoglycemia (NS or SH, respectively). METHODS: We included subjects (1) older than 18 years, (2) with T1D duration of >5 years, (3) on multiple doses of insulin, and (4) without micro- or macrovascular complications and more than four NS events per week (in the last 8 weeks) and more than two SH events (in the last 2 years). NS/SH episodes and hypoglycemia awareness were evaluated. A 72-h continuous glucose monitoring (CGM) was performed before continuous subcutaneous insulin infusion (CSII). A hypoglycemia-induced test was used to evaluate each patient's symptoms in euglycemia/hypoglycemia. Quality of life (QoL) was also evaluated. After 6, 12, and 24 months, all the subjects were reevaluated. RESULTS: Twenty subjects were included (34.0 +/- 7.5 years old, 12 women, A1c 6.7 +/- 1.1%, 16.2 +/- 6.6 years of diabetes' duration). At baseline, 19 out of 20 subjects displayed hypoglycemia unawareness, which diminished significantly during the follow-up (3 out of 20). NH episodes per week diminished from 5.40 +/- 2.09 at baseline to 2.75 +/- 1.74 at the end of the follow-up (P < 0.001). SH episodes fell from 1.25 +/- 0.44 per subject-year to 0.05 +/- 0.22 after 24 months (P < 0.001). Hemoglobin A1c remained unaltered. With CGM, the percentage of values within 70-180 mg/dL increased (53.2 +/- 11.0% to 60.3 +/- 17.1%, P = 0.13), and the percentage of values <70 mg/dL decreased (13.7 +/- 9.4% to 9.1 +/- 5.2%, P = 0.07), after 24 months. Mean amplitude of glycemic excursions diminished after 24 months of CSII (136 +/- 28 mg/dL to 115 +/- 19 mg/dL; P < 0.02). An improvement in all the aspects of QoL was observed. The basal alteration in symptom response to an induced hypoglycemia improved after 24 months of initiating CSII leading to a response indistiguishable from that observed in a control group of subjects with T1D without repeated NH and SH. CONCLUSIONS: CSII prevents hypoglycemic episodes, improves hypoglycemia awareness, and ameliorates glycemic profile in T1D subjects with repeated NS/SH. Its use is also associated with an improvement in diabetes QoL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Epidemiology of severe hypoglycemia in the diabetes control and complications trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)80085-z · Cited by 807 · cited 1×
“1,2 However, the price to pay is an increase in NH and SH episodes (two-to threefold).”
Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90605-w · Cited by 807
Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794
Clarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651
Fanelli, C. G., Epifano, L., Rambotti, A. M., Pampanelli, S., Di Vincenzo, A., Modarelli, F., Lepore, M., Annibale, B., Ciofetta, M., Bottini, P., et al. (1993) · Diabetes · doi:10.2337/diab.42.11.1683 · Cited by 398
Symptoms of hypoglycaemia in people with diabetes
McAulay, V., Deary, I. J., & Frier, B. M. (2001) · Diabetic Medicine · doi:10.1046/j.1464-5491.2001.00620.x · Cited by 264
Blood Glucose Awareness Training (BGAT-2)
Cox, D. J., Gonder-Frederick, L., Polonsky, W., Schlundt, D., Kovatchev, B., & Clarke, W. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.637 · Cited by 235
Intensified insulin therapy and the risk of severe hypoglycaemia
Bott, S., Bott, U., Berger, M., & Mühlhauser, I. (1997) · Diabetologia · doi:10.1007/s001250050769 · Cited by 180
Restoration of hypoglycemia awareness after islet transplantation
Leitão, C. B., Tharavanij, T., Cure, P., Pileggi, A., Baidal, D. A., Ricordi, C., & Alejandro, R. (2008) · Diabetes Care · doi:10.2337/dc08-0741 · Cited by 101 · cited 1×
“In absolute terms, and acknowledging the differences between both studies, the magnitude of restoration of hypoglycemia awareness achieved in our study using CSII is quite similar to that observed by Leita˜o et al. 31 using islet transplantation.”
Cox, D. J., Kovatchev, B., Kovatchev, B., Koev, D., Koeva, L., Dachev, S., Tcharaktchiev, D., Protopopova, A., Gonder-Frederick, L., & Clarke, W. (2004) · International Journal of Behavioral Medicine · doi:10.1207/s15327558ijbm1104_4 · Cited by 88
Cited by
Choudhary, P., Rickels, M. R., Senior, P. A., Vantyghem, M.-C., Maffi, P., Kay, T. W., Keymeulen, B., Inagaki, N., Saudek, F., Lehmann, R., et al. (2015) · Diabetes Care · doi:10.2337/dc15-0090 · Cited by 233
Mechanisms of hypoglycemia unawareness and implications in diabetic patients
Martín-Timón, I. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i7.912 · Cited by 204
Yeoh, E., Choudhary, P., Nwokolo, M., Ayis, S., & Amiel, S. A. (2015) · Diabetes Care · doi:10.2337/dc15-0102 · Cited by 154
Lucidi, P., Porcellati, F., Bolli, G. B., & Fanelli, C. G. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1065-6 · Cited by 38
Metadata
- Authors
- Giménez, M., Lara, M., & Conget, I.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2010-07
- Volume
- 12
- Issue
- 7
- Pages
- 517-521
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W1964657944
- Cited by
- 38
- References
- 12
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.